tetano
Editor, Senior Moderator
Nat Cancer
. 2022 Dec 21.
doi: 10.1038/s43018-022-00502-x. Online ahead of print.
Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma
Andrea Keppler-Hafkemeyer[SUP] #[/SUP][SUP] 1 [/SUP], Christine Greil[SUP] #[/SUP][SUP] 2 [/SUP], Paul R Wratil[SUP] #[/SUP][SUP] 3 4 [/SUP], Khalid Shoumariyeh[SUP] #[/SUP][SUP] 2 5 [/SUP], Marcel Stern[SUP] #[/SUP][SUP] 3 [/SUP], Annika Hafkemeyer[SUP] 2 [/SUP], Driti Ashok[SUP] 2 [/SUP], Alexandra Hollaus[SUP] 6 [/SUP], Gaia Lupoli[SUP] 3 [/SUP], Alina Priller[SUP] 7 [/SUP], Marie L Bischof[SUP] 3 [/SUP], Gabriele Ihorst[SUP] 8 [/SUP], Monika Engelhardt[SUP] 2 [/SUP], Reinhard Marks[SUP] 2 [/SUP], Jürgen Finke[SUP] 2 [/SUP], Hannah Bertrand[SUP] 2 [/SUP], Christopher Dächert[SUP] 3 4 [/SUP], Maximilian Muenchhoff[SUP] 3 4 [/SUP], Irina Badell[SUP] 3 4 [/SUP], Florian Emmerich[SUP] 9 [/SUP], Hridi Halder[SUP] 6 [/SUP], Patricia M Spaeth[SUP] 3 [/SUP], Percy A Knolle[SUP] 4 7 [/SUP], Ulrike Protzer[SUP] 4 10 11 [/SUP], Michael von Bergwelt-Baildon[SUP] 5 6 [/SUP], Justus Duyster[SUP] 2 [/SUP], Tanja N Hartmann[SUP] 2 [/SUP], Andreas Moosmann[SUP] 4 5 6 10 [/SUP], Oliver T Keppler[SUP] 12 13 [/SUP]
Affiliations
Abstract
Individuals with hematologic malignancies are at increased risk for severe coronavirus disease 2019 (COVID-19), yet profound analyses of COVID-19 vaccine-induced immunity are scarce. Here we present an observational study with expanded methodological analysis of a longitudinal, primarily BNT162b2 mRNA-vaccinated cohort of 60 infection-naive individuals with B cell lymphomas and multiple myeloma. We show that many of these individuals, despite markedly lower anti-spike IgG titers, rapidly develop potent infection neutralization capacities against several severe acute respiratory syndrome coronavirus 2 variants of concern (VoCs). The observed increased neutralization capacity per anti-spike antibody unit was paralleled by an early step increase in antibody avidity between the second and third vaccination. All individuals with hematologic malignancies, including those depleted of B cells and individuals with multiple myeloma, exhibited a robust T cell response to peptides derived from the spike protein of VoCs Delta and Omicron (BA.1). Consistently, breakthrough infections were mainly of mild to moderate severity. We conclude that COVID-19 vaccination can induce broad antiviral immunity including ultrapotent neutralizing antibodies with high avidity in different hematologic malignancies.
. 2022 Dec 21.
doi: 10.1038/s43018-022-00502-x. Online ahead of print.
Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma
Andrea Keppler-Hafkemeyer[SUP] #[/SUP][SUP] 1 [/SUP], Christine Greil[SUP] #[/SUP][SUP] 2 [/SUP], Paul R Wratil[SUP] #[/SUP][SUP] 3 4 [/SUP], Khalid Shoumariyeh[SUP] #[/SUP][SUP] 2 5 [/SUP], Marcel Stern[SUP] #[/SUP][SUP] 3 [/SUP], Annika Hafkemeyer[SUP] 2 [/SUP], Driti Ashok[SUP] 2 [/SUP], Alexandra Hollaus[SUP] 6 [/SUP], Gaia Lupoli[SUP] 3 [/SUP], Alina Priller[SUP] 7 [/SUP], Marie L Bischof[SUP] 3 [/SUP], Gabriele Ihorst[SUP] 8 [/SUP], Monika Engelhardt[SUP] 2 [/SUP], Reinhard Marks[SUP] 2 [/SUP], Jürgen Finke[SUP] 2 [/SUP], Hannah Bertrand[SUP] 2 [/SUP], Christopher Dächert[SUP] 3 4 [/SUP], Maximilian Muenchhoff[SUP] 3 4 [/SUP], Irina Badell[SUP] 3 4 [/SUP], Florian Emmerich[SUP] 9 [/SUP], Hridi Halder[SUP] 6 [/SUP], Patricia M Spaeth[SUP] 3 [/SUP], Percy A Knolle[SUP] 4 7 [/SUP], Ulrike Protzer[SUP] 4 10 11 [/SUP], Michael von Bergwelt-Baildon[SUP] 5 6 [/SUP], Justus Duyster[SUP] 2 [/SUP], Tanja N Hartmann[SUP] 2 [/SUP], Andreas Moosmann[SUP] 4 5 6 10 [/SUP], Oliver T Keppler[SUP] 12 13 [/SUP]
Affiliations
- PMID: 36543907
- DOI: 10.1038/s43018-022-00502-x
Abstract
Individuals with hematologic malignancies are at increased risk for severe coronavirus disease 2019 (COVID-19), yet profound analyses of COVID-19 vaccine-induced immunity are scarce. Here we present an observational study with expanded methodological analysis of a longitudinal, primarily BNT162b2 mRNA-vaccinated cohort of 60 infection-naive individuals with B cell lymphomas and multiple myeloma. We show that many of these individuals, despite markedly lower anti-spike IgG titers, rapidly develop potent infection neutralization capacities against several severe acute respiratory syndrome coronavirus 2 variants of concern (VoCs). The observed increased neutralization capacity per anti-spike antibody unit was paralleled by an early step increase in antibody avidity between the second and third vaccination. All individuals with hematologic malignancies, including those depleted of B cells and individuals with multiple myeloma, exhibited a robust T cell response to peptides derived from the spike protein of VoCs Delta and Omicron (BA.1). Consistently, breakthrough infections were mainly of mild to moderate severity. We conclude that COVID-19 vaccination can induce broad antiviral immunity including ultrapotent neutralizing antibodies with high avidity in different hematologic malignancies.